Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 5, 1999, Pages 381-395

  Breitz, Hazel B ^a   Fisher, Darrell R ^b   Goris, Michael L ^c   Knox, Susan ^c   Ratliff, B ^a   Murtha, Albert D ^d   Weiden, Paul L ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^c CROSS CANCER INSTITUTE   (Canada)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dosimetry; Pretargeted radioimmunotherapy; PRIT; RIT; Y 90 dosimetry

Indexed keywords

ANTIBODY; BIOTIN; INDIUM 111; STREPTAVIDIN; YTTRIUM 90;

ARTICLE; BONE MARROW TOXICITY; BREMS RADIATION; CLINICAL ARTICLE; DIARRHEA; DOSIMETRY; DRUG RESPONSE; DRUG TARGETING; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA;

EID: 0032842220     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.381     Document Type: Article

References (33)

1. Breitz HB, Weiden PL, Vanderheyden J-L, et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 1992; 33: 1099-1112.
2. Meredith RM, Khazaeli MB, Plott WE, et al. Phase I trial of iodine-131-chimeric B72.3 in metastatic colorectal cancer. J Nucl Med 1992;33:23-29.
3. Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial. J Clin Oncol 1997;15(4):1518-1528.
4. 90Y Mx-diethylenetriaminepentaacetic acid (DPTA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: A phase I trial. Cancer Res Suppl 1995; 55(23):5921s.
5. Goodwin DA. Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins. Eur J Nucl Med 1984;9:209-215.
6. Breitz HB, Weiden PL, Beaumier P, et al. Pretargeted radioimmunotherapy (PRIT) using antibody-streptavid-in conjugate and radiobiotin: Phase I Study to optimize therapy protocol. J Nucl Med In press.
7. Divgi, CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995; 26 (4): 586-592.
8. 2 antibodies. Br J. Cancer 1994; 70: 521-525.
9. Kramer EL, Liebes L, Wasserheit C, et al. Initial evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Can Res 1998; 4: 1679-1688.
10. Breitz H, Knox S, Weiden P, et al. Pretargeted radioimmunotherapy with antibody streplavidin and Y-90 DOTA-biotin (Avicidin). Results of a dose escalation study. J Nucl Med 1998; 39(5): 71P
11. Taylor A, Lewis C, Giacometti A, Hall EC, Barefield KP. Improved formulas for the estimation of renal depth in adults. J Nucl Med 1993; 34(10): 1766-1769.
12. Su F-M, Hickey JJ, Taylor C, Beaumier P. In-111/Y-90 dual isotope scintillation counting method for patient samples from pretargeted cancer therapy phase I trial. J Nucl Med 1996; 37(5): 145P.
13. Breitz HB, Fisher DR, Weiden PL, et al. Dosimetry of rhenium-186-labeled monoclonal antibodies: Methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. J Nucl Med 1993; 34:908-917.
14. Okabe T, Kaizu T, Fujisawa J, et al. Monoclonal antibodies to surface antigens of small cell carcinoma of the lung. Cancer Res 1984; 44, 5273-5278.
15. ICRU. Methods of assessment of absorbed dose in clinical use of radionuclides. In: International Commission on Radiation Units and Measurements, (ICRU) report no. 32. Washington, DC 1979.
16. NRCP. The experimental basis for absorbed dose calculations, in: Medical uses of radionuclides. National Council on Radiation Protection and Measurements, report No. 83. Bethesda, MD: 1985.
17. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York: Society of Nuclear Medicine, 1988.
18. Snyder WS, Ford MR, Warner GG. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogenous phantom. In: MIRD pamphlet no. 5 revised. New York: Society of Nuclear Medicine; 1978:5-67.
19. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibod Immunoconjug and Radiopharm 1990; 3:213-233.
20. Fisher DR, Badger CC, Breitz HB et al. Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies. Antib Immunoconjug and Radiopharm 1991; 4:655-664.
21. Vargo JG.MIRDOSE, Revision 2 (Software Review). Hlth Phys 1989; 57: 764.
22. Eve IS. A review of the physiology of the gastrointestinal tract in relation to radiation absorbed doses from radioactive materials. Hlth Phys 1966; 12:131-161.
23. Fisher, DR, Rajon D, Bolch, WE, Breitz HB. Dosimetry Model for Radiolabeled Antibodies in Gastrointestinal Mucosa. Cancer Biotherapy & Radiopharm 1998; 13:301 (abstract).
24. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria for the Eastern Cooperative Group. Am J Clin Onccol 1982; 5: 649-655.
25. Sgouros G, Divgi CR, Scott AM, Williams J, Larson SM. Hematological toxicity in radioimmunotherapy: An evaluation of different predictive measures. J Nucl Med 1996; 37(5) Suppl: 44P.
26. Breitz HB, Fisher DR, Wessels BW. Marrow toxicity and radiation absorbed dose. J Nucl Med 1998:39 (10): 1746-1751.
27. 131I-Lym-1 as a model. Cancer 1994; 73(3) Suppl: 1038-1048.
28. Liu T, Meredith R, Saleh M,et al. Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in Three Phase II clinical trials. Cancer Biotherapy & Radiopharm 1997; 12(2):79-87.
29. Stubbs JB, Valenzuela GA, Stubbs CC, Croft BY, Teates CD, Plankey MW, McCallum PW. A noninvasive scintigraphic assessment of the colonic transit of nondigestible solids in man. J Nucl Med 1991; 32: 1375 B 1381.
30. Eising EG, von der Ohe MR. Differentiation of prolonged colonic transit using scintigraphy with indium-111-labeled polystyrene pellets. J Nucl Med 1998; 39: 1062 B 1066.
31. Stubbs JB, Evans JF, Stabin MG. Radiation absorbed dose to the walls of hollow organs. J Nucl Med 1998; 39 (11): 1989 B 1995.
32. Kasiske BL, Umen AJ. The influence of age, race and body habitus on kidney weight in humans. Arch Pathol Lab Med 1986; 110 (1): 55-60.
33. Zhu H, Jain RK, Baxter LT. Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med 1998; 39(1): 65-76.